Advisory Services Network LLC Cuts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Advisory Services Network LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 60.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,218 shares of the medical equipment provider's stock after selling 3,326 shares during the quarter. Advisory Services Network LLC's holdings in Zimmer Biomet were worth $234,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ZBH. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $473,000. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet in the fourth quarter worth about $7,825,000. Peddock Capital Advisors LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $654,000. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after purchasing an additional 218,688 shares during the period. Finally, Reinhart Partners LLC. raised its position in Zimmer Biomet by 34.4% during the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock valued at $9,164,000 after purchasing an additional 22,220 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $1.28 during midday trading on Thursday, reaching $100.73. 378,746 shares of the stock were exchanged, compared to its average volume of 1,656,209. The firm has a market cap of $19.93 billion, a price-to-earnings ratio of 22.61, a PEG ratio of 1.95 and a beta of 0.84. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a 50-day simple moving average of $105.80 and a two-hundred day simple moving average of $106.57. Zimmer Biomet Holdings, Inc. has a twelve month low of $93.10 and a twelve month high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company posted $2.20 earnings per share. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Raymond James reduced their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, JMP Securities restated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.